Johnson & Johnson (NYSE:JNJ) Stock Price Down 2.3% – What’s Next?

Johnson & Johnson (NYSE:JNJ) shares were down 2.3% during trading on Tuesday . The company traded as low as $266.88 and last traded at $269.0370. 7,767,583 shares changed hands during trading, a decline of 4% from the average daily volume of 8,120,712 shares. The stock had previously closed at $275.23.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J received CE Marking for its ACUVUE OASYS MAX 2-Week reusable contact lenses, allowing the product to be marketed in eligible European markets. The launch expands the company’s vision-care portfolio and could support future sales, although the near-term earnings impact is likely limited. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
• Positive Sentiment: Chinese regulators approved Icotyde, J&J’s once-daily oral treatment for moderate-to-severe plaque psoriasis. The approval gives the company another treatment option in China’s large psoriasis market and may broaden growth prospects beyond injectable therapies. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
• Neutral Sentiment: Recent investor commentary has highlighted J&J’s focus on higher-end MedTech growth, particularly cardiovascular products. The strategy could strengthen the company’s long-term growth profile, but investors may want evidence of sustained adoption and improving returns before assigning a higher valuation. Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage
• Negative Sentiment: Analysts are questioning whether J&J’s recent rally has lost momentum. With shares trading well above their 200-day moving average and at a P/E ratio near 31, profit-taking and concerns that favorable expectations are already reflected in the stock could be weighing on sentiment. JNJ Stock: Is the Rally Running Out of Steam?

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Guggenheim increased their target price on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. HSBC lifted their price objective on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings raised Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Finally, Bank of America lifted their price target on Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $274.13.

Johnson & Johnson Stock Down 0.3%

The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The business has a 50-day simple moving average of $262.88 and a 200-day simple moving average of $245.62. The stock has a market cap of $641.76 billion, a P/E ratio of 30.86, a PEG ratio of 2.57 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts expect that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s payout ratio is currently 62.11%.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 87,569 shares of company stock valued at $23,064,544 over the last three months. 0.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds have recently made changes to their positions in the stock. Elefante Mark B lifted its stake in Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock valued at $7,285,000 after purchasing an additional 2,563 shares during the last quarter. World Investment Advisors raised its stake in shares of Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after buying an additional 26,450 shares during the period. Signal Advisors Wealth LLC lifted its position in shares of Johnson & Johnson by 76.1% during the 1st quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after buying an additional 6,539 shares during the last quarter. Gradient Investments LLC increased its holdings in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock worth $38,815,000 after acquiring an additional 13,737 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new stake in Johnson & Johnson in the 1st quarter valued at about $30,017,000. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.